A Phase IIa Study of JAB-8263 in Patients With Active Rheumatoid Arthritis

Study acronym: JAB-8263
StatusRecruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Recruitment opened Show 4 more changesShow less
    • Start date changed from estimate of Jul 29, 2026 to Jul 23, 2026
    • Eligibility criteria shortened, about 13 words
    • Secondary endpoints: details revised at 5 of 5 entries
    • Site details revised
  2. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
This study is an open-label, multi-center Phase IIa study. The study is divided into two phases. The first phase is a safety exploration phase. Participants with active rheumatoid arthritis were enrolled and treated with JAB-8263 alone for 4 weeks. The purpose is to evaluate the safety, PK/PD characteristics and preliminary effectiveness of JAB-8263 in participants with active RA.
Trial Details
NCT Number NCT07684157
Lead Sponsor Jacobio Pharmaceuticals Co., Ltd.
Conditions
(from sponsor)		 Rheumatoid Arthritis (RA)
Related terms Arthritis, Rheumatoid
Enrollment 32 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov